Breaking News

Janssen Completes Divestiture

U.S. license rights to Nucynta family of products sold to Depomed

Janssen Pharmaceuticals, Inc. has completed the divestiture of its U.S. license rights to Nucynta (tapentadol), Nucynta ER extended-release tablets and Nucynta oral solution to Depomed for $1.05 billion.

Janssen’s licensed U.S. commercialization rights to Nucynta products from Grunenthal GmbH were assigned to Depomed. Janssen will retain license rights to the products in Canada, Japan, and a number of other countries outside the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters